TECHNETIUM TC 99M ALBUMIN AGGREGATED

drug
On this page

Also known as An-maaMacrotecPulmolitePulmotech maaTC99M-MP 4006TC99M-MP-4006Technescan maaTechnetium tc 99m maaTechnetium tc-99m albumin aggregatedTechnetium tc-99m albumin aggregated kitTechnetium tc-99m albumin colloid kit

Summary

Technetium Tc 99M Albumin Aggregated (CHEMBL1201522) is an approved protein.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Protein
  • Clinical trials: 4

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1201522
NameTECHNETIUM TC 99M ALBUMIN AGGREGATED
TypeProtein
Max phase4

Also known as: An-maa, Macrotec, Pulmolite, Pulmotech maa, TC99M-MP 4006, TC99M-MP-4006, Technescan maa, Technetium tc 99m albumin aggregated, Technetium tc 99m maa, Technetium tc-99m albumin aggregated, Technetium tc-99m albumin aggregated kit, Technetium tc-99m albumin colloid kit

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 4.

Phase distribution

PhaseTrials
PHASE21
EARLY_PHASE11
PHASE11
Not specified1

Top trials by phase / activity

NCTPhaseStatusTitle
NCT02773238PHASE2COMPLETEDFLARE RT for Patients With Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT Imaging
NCT03028311PHASE1ACTIVE_NOT_RECRUITINGYttrium Y-90 Radioembolization in Treating Patients With Metastatic Liver Cancer
NCT01034514EARLY_PHASE1TERMINATED4D-CT-based Ventilation Imaging for Adaptive Functional Guidance in Radiotherapy
NCT01982123Not specifiedCOMPLETEDSPECT/CT in Measuring Lung Function in Patients With Cancer Undergoing Radiation Therapy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.